**Biography:** James Kennedy, Board of Directors

Dr Kennedy completed medical school and internship at the University of Calgary, Canada followed by his Psychiatry Residency and Human Genetics postdoctoral fellowship at Yale University, USA. He returned to Canada in 1991 to be head of the Neurogenetics Section at what is now the Centre for Addiction and Mental Health (CAMH). He is currently Director of Molecular Brain Science Department and Head of the Tanenbaum Centre for Pharmacogenetics at CAMH. In 2000, he became Full Professor in the Department of Psychiatry at the University of Toronto and is Co-Head of the Brain and Therapeutics Division.

Dr. Kennedy has training in three major areas: neuroscience, clinical psychiatry, and molecular genetics. His main research interest over the past 25 years has been the identification of genetic causes of psychiatric disorders, genetic predictors of brain structure and function via MRI and PET, and pharmacogenetics. His discoveries include: 1) the role of the DRD4 gene in ADHD, 2) the DRD3 gene predicting risk for Tardive Dyskinesia, 3) the 5HTTLPR genetic marker predicts risk for antidepressant induced mania, and several genes that predict antipsychotic response.

Major current projects led by Dr. Kennedy include the Individualized Medicine: Pharmacogenetic Assessment and Clinical Treatment (IMPACT) study examining a large sample (N=20,000) of patients to discover new pharmacogenetic markers, and determine the usefulness and cost-benefit of genetic testing applied to choice and dosage of psychiatric medications in clinical care. Furthermore, he is leading a large randomized controlled clinical trial of pharmacogenomic tests in 1,200 depression and schizophrenia patients, funded by Genome Canada. Dr. Kennedy has published more than 600 scientific articles with over 25,000 citations. He is an active lecturer at numerous international conferences and in 2013, became a Fellow of the Royal Society of Canada.